Clinical trial
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage…
NCT00004025 · Genzyme, a Sanofi Company, Industry · Unknown status
Key facts
| NCT number | NCT00004025 |
|---|---|
| Title | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma |
| Official title | Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of Autologous Dendritic Cells Transduced With Adenoviruses Encoding the MART-1 and gp100 Melanoma Antigens Administered With or Without Low Dose Recombinant Interleukin-2 (rIL-2) in Patients With Stage IV Melanoma |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | aldesleukin, dendritic cell-gp100-MART-1 antigen vaccine |
| Enrollment | 36 |
| Start date | Mar 1, 1999 |
| First posted | Oct 29, 2003 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: